With federal research funding drying up, Harvard University is turning to an unconventional source to keep its scientific work alive. A major financial partnership between Harvard's T.H. Chan School of Public Health and Turkish private equity firm İşPrivate Equity is setting a new precedent for research finance. This $39 million deal targets the genetics and metabolism lab of Professor Gökhan Hotamışlıgil, a critical move as government grants become less dependable.
Key Details of the Investment
İşPrivate Equity, a subsidiary of Turkey’s İşbank Group, will inject $39 million directly into the lab, ensuring its core operations and research initiatives continue. The agreement goes further: the firm has also committed to support any promising drug candidates that emerge, advancing them into the clinical stage via a new biotech venture, Enlila.
- $39 million for essential lab functions and innovative research
- Follow-on capital for commercializing discoveries through Enlila
- Alignment of investor and academic interests for greater translational impact
Navigating Federal Funding Cuts
Harvard's move reflects a broader trend among universities seeking private-sector solutions as federal support unpredictably contracts. Recent policy changes have left institutions scrambling to find reliable funding. University leaders now view this private equity partnership as a potentially scalable model for other research centers facing similar budget constraints.
- Declining federal grants threaten a wide range of scientific programs
- Universities increasingly look to private capital to sustain research
- This partnership is a proof of concept for private equity in academia
What Sets This Deal Apart?
Unlike traditional corporate-sponsored research, this arrangement features direct private equity investment in a university lab, coupled with the creation of a biotech company to commercialize breakthroughs. The approach enables both Harvard and İş Private Equity to share risk and reward as they push new therapies for metabolic diseases toward market.
- İş Private Equity obtains early access to cutting-edge science and commercial opportunity
- Harvard lab enjoys long-term, flexible funding
- Enlila bridges the gap between academic innovation and industry application
Implications for the Future of Research Funding
The Harvard Private Equity partnership may influence other institutions to consider similar funding structures, especially as public dollars dwindle. By partnering directly with investors, universities could accelerate the development and commercialization of research discoveries.
However, this model also prompts careful examination of academic freedom, intellectual property, and the influence of profit motives on science. Striking the right balance between public benefit and private interests will be essential as these collaborations become more common.
Join the Conversation - A Forum For Ideas
The assult on university research by the Trump Administration is simply unprecedented and indicates our immediate need for funding alternatives. To help the community brainstorm and collaborate I have setup a forum to discuss alternative funding ideas. I encourage you to review and participate to help uncover novel ways to save our academic research institutions and mitigate political interference in the sciences and humanities. Visit https://joshuaberkowitz.us/forum to get started!
Takeaway
The $39 million deal between Harvard and İş Private Equity illustrates an emerging path forward for research funding. As federal support becomes less reliable, such partnerships could help universities sustain groundbreaking science and streamline the journey from discovery to real-world impact. The evolution of this collaboration will be closely monitored by the academic and investment communities alike.
Private Equity Reshapes Harvard Lab Funding as Federal Support Wanes